UK Research Could Pave Way for Noonan-like Syndrome Treatment

University of Kentucky researcher Emilia Galperin has been awarded a $1.9 million grant to continue her research examining cell signal pathways and genetic disease. Pete Comparoni | UK Photo.
University of Kentucky researcher Emilia Galperin has been awarded a $1.9 million grant to continue her research examining cell signal pathways and genetic disease. Pete Comparoni | UK Photo.

LEXINGTON, Ky. (July 1, 2020) — A University of Kentucky College of Medicine researcher has been awarded $1.9 million to continue research examining molecular pathogenesis of Noonan-like syndrome.

Emilia Galperin, Ph.D., professor in the Department of Molecular & Cellular Biochemistry, was awarded a prestigious R35 Maximizing Investigator’s Research Award Grant from the National Institute of General Medical Sciences that will fund her lab’s research over the next five years.

Normal human cell growth is controlled by complex signaling pathways, and errors in these signal transmissions can have serious consequences including tumor formation or developmental diseases.

Galperin’s lab is focused on signaling pathways in the cell called extracellular signal-regulated kinases 1 and 2 (ERK1/2), which are essential for several critical steps of human development. ERK1/2 contains a protein called Shoc2, which allows efficient signal transmission.

Shoc2 mutations cause Noonan-like syndrome, a genetic disorder that causes unusual facial characteristics, short stature, heart defects present at birth, bleeding problems, developmental delays, and malformations of the bones of the rib cage.

Galperin’s study aims to understand how Shoc2 is involved in determining genetic diseases, which is not currently well-understood. It will also lay the groundwork for future studies on developmental disorders and contribute to the advancement of drug development for diseases of the same group as Noonan-like syndrome, which affects about 1 in about 1,000-2,500 people.

Noonan syndrome was named after Dr. Jacqueline Noonan, a pediatric cardiologist who served as a faculty member in UK’s College of Medicine for more than 40 years. Noonan, one of the most important individuals in the history of American pediatric care, is internationally known for her description and characterization in 1962 of the genetic disorder.

Galperin’s lab has developed a model for Shoc2 deficiency in zebrafish and established that loss of Shoc2 can cause the same early development congenital malformations observed in patients with Shoc2 mutations.

“The Shoc2 protein seems to be vastly understudied and we have already contributed quite a bit of basic understanding,” said Galperin. “This is necessary not only to better understand what exactly is happening in the progression of the disease, but to get a basic understanding of how it works before pursuing potential drug development.”


The University of Kentucky is increasingly the first choice for students, faculty and staff to pursue their passions and their professional goals. In the last two years, Forbes has named UK among the best employers for diversity, and INSIGHT into Diversity recognized us as a Diversity Champion three years running. UK is ranked among the top 30 campuses in the nation for LGBTQ* inclusion and safety. UK has been judged a “Great College to Work for" two years in a row, and UK is among only 22 universities in the country on Forbes' list of "America's Best Employers."  We are ranked among the top 10 percent of public institutions for research expenditures — a tangible symbol of our breadth and depth as a university focused on discovery that changes lives and communities. And our patients know and appreciate the fact that UK HealthCare has been named the state’s top hospital for four straight years. Accolades and honors are great. But they are more important for what they represent: the idea that creating a community of belonging and commitment to excellence is how we honor our mission to be not simply the University of Kentucky, but the University for Kentucky.